Tirzepatide is FDA-approved — here is what the 2024–2025 safety and trial record actually shows.

The short version

Tirzepatide is a prescription medicine the FDA first approved in May 2022 for type 2 diabetes, then in November 2023 for chronic weight management, and later for obstructive sleep apnea in adults with obesity. It is a synthetic peptide — 39 amino acids — that activates two gut-hormone receptors at once: the GIP receptor and the GLP-1 receptor. This dual action is what sets it apart from older weight and diabetes medicines, which targeted only GLP-1. In large Phase 3 trials, it produced the largest average weight losses ever recorded in a randomized obesity drug trial — up to about 21% of body weight in 72 weeks. The most common downsides are digestive: nausea, vomiting, constipation, and diarrhea, most intense during dose increases and usually fading with time. Some safety signals — including gallbladder disease and lean-muscle loss — are monitored closely by researchers. A boxed warning on the label covers a rodent-derived thyroid tumor signal, which has not been confirmed in humans. What people report, what the safety meta-analyses measured, and what to watch out for is documented on the effects page.

What is tirzepatide

Tirzepatide (international nonproprietary name; CAS 2023788-19-2; ATC A10BX16) is a 39-amino-acid synthetic peptide engineered from the native GIP hormone sequence. A C20 fatty-diacid (eicosanedioic acid) arm, attached via a glutamic acid linker and two aminoethoxyethoxy acetic acid units to a lysine side chain, gives the molecule high albumin affinity and a plasma half-life of approximately five days — the pharmacokinetic basis of once-weekly subcutaneous dosing. Molecular weight: 4,813.53 Da. Molecular formula: C225H348N48O68. The dual GIP/GLP-1 agonist hypothesis — a so-called twincretin or unimolecular dual incretin mimetic — posited that engaging both incretin receptors simultaneously would produce larger glycaemic and body-weight reductions than any single incretin agent. The Phase 3 programmes confirmed it. Coskun et al. (2018) documented the discovery, proof-of-concept preclinical data, and Phase 1 human programme in 142 subjects, showing that the molecule activated both GIP and GLP-1 signalling in vitro, reduced body weight and food intake more than a selective GLP-1 receptor agonist in mice, and supported once-weekly human dosing ^[1]. Willard et al. (2020) characterised the molecule's pharmacology in detail: tirzepatide engages the GIP receptor more fully than the GLP-1 receptor (an imbalanced dual agonist) and exhibits biased GLP-1 receptor signalling, favouring cAMP generation over beta-arrestin recruitment — a pharmacological profile that may enhance insulin secretion ^[2]. These mechanistic properties underpin the clinical results.

Tirzepatide results — what the Phase 3 trials measured

The SURPASS programme (type 2 diabetes) and SURMOUNT programme (obesity) collectively enrolled tens of thousands of participants across multiple randomised controlled trials. The headline figures:

SURPASS-2 (n=1,879, 40 weeks) — tirzepatide 5, 10, and 15 mg once weekly reduced HbA1c (glycated haemoglobin — the standard blood-glucose marker averaged over three months) by 2.01, 2.24, and 2.30 percentage points respectively, versus 1.86 points with the comparator at 1 mg; tirzepatide was non-inferior and superior at all three doses. Body weight reductions were greater with tirzepatide (treatment differences versus comparator: -1.9, -3.6, and -5.5 kg). Most adverse events were gastrointestinal and mild to moderate ^[3].

SURMOUNT-1 (n=2,539, 72 weeks) — in adults with obesity but without type 2 diabetes, mean weight change at week 72 was -15.0% (5 mg), -19.5% (10 mg), and -20.9% (15 mg) versus -3.1% with placebo. Adverse events were again predominantly gastrointestinal, most frequent during dose escalation ^[4].

SURMOUNT-5 (n=751, 72 weeks, published 2025) — a head-to-head comparison against the highest approved maintenance dose of the comparator; mean weight change was -20.2% with tirzepatide versus -13.7% with the comparator (P<0.001). Tirzepatide also produced greater waist circumference reductions and higher proportions reaching 10%, 15%, 20%, and 25% weight-loss thresholds ^[5].

SYNERGY-NASH (published 2024) — in adults with metabolic dysfunction-associated steatohepatitis (MASH — a progressive fatty liver disease formerly called NASH) and moderate-to-severe fibrosis, tirzepatide produced higher rates of MASH resolution without worsening of fibrosis versus placebo ^[9].

SURMOUNT-OSA (2024) and SUMMIT (heart failure with preserved ejection fraction, 2025) extended the approved indication landscape beyond glucose and weight ^[10][17].

For the tirzepatide weight loss evidence in depth, including the 2025 diabetes-prevention readout, see the dedicated page.

Tirzepatide vs semaglutide — what the direct comparison showed

The 2025 SURMOUNT-5 trial is the only large randomised head-to-head comparison of tirzepatide and semaglutide (a selective GLP-1 receptor agonist) for weight management. In 751 adults with obesity but without type 2 diabetes, tirzepatide at the maximum tolerated dose (10 or 15 mg) produced a -20.2% mean body-weight change at 72 weeks versus -13.7% with semaglutide at the maximum tolerated dose (1.7 or 2.4 mg) — a statistically significant difference (P<0.001) ^[5]. Tirzepatide also achieved higher rates of reaching each weight-loss threshold. In the SURPASS-2 diabetes trial, head-to-head over 40 weeks, tirzepatide outperformed semaglutide 1 mg on both HbA1c reduction and weight at all three tirzepatide doses ^[3]. The mechanistic explanation sits in the dual-agonist pharmacology: engaging the GIP receptor in addition to the GLP-1 receptor appears to produce incremental weight and glucose benefit over GLP-1 receptor agonism alone, consistent with the original mouse data from Coskun et al. ^[1].

Tirzepatide peptide — the molecular story behind the dual action

Tirzepatide peptide is not an endogenous hormone — it is a fully synthetic construct engineered from the native GIP backbone, modified with a fatty-diacid acylation arm that extends its plasma half-life from minutes (endogenous GIP's duration) to approximately five days. The molecule activates the GIP receptor (GIPR) and the GLP-1 receptor (GLP-1R) simultaneously. The GIP receptor (glucose-dependent insulinotropic polypeptide receptor) and GLP-1 receptor (glucagon-like peptide-1 receptor) are both incretin receptors — gut-hormone sensors expressed on pancreatic beta cells and at sites in the brain, fat, and gut. Engaging both triggers glucose-dependent insulin secretion (more insulin when blood glucose is high), glucagon suppression (less liver glucose output), slowed gastric emptying (food leaves the stomach more slowly, blunting post-meal glucose spikes), and reduced appetite via central nervous system pathways. Campbell et al. (2023) reviewed the chemistry and physiology of dual GIP/GLP-1 agonism as a drug class, providing mechanistic context for the observed clinical effects ^[13].

Tirzepatide reviews — what the evidence base looks like

As of mid-2025 tirzepatide has one of the most extensive newly-approved drug evidence bases in metabolic medicine. The SURPASS programme (five trials in type 2 diabetes, including a cardiovascular outcomes trial) and the SURMOUNT programme (five trials in obesity, sleep apnea, and associated conditions) are supplemented by dedicated readouts in MASH (SYNERGY-NASH) and heart failure with preserved ejection fraction (SUMMIT). The 2026 meta-analysis by Qazi et al. of nine trials versus dulaglutide confirmed greater glycaemic and weight efficacy but flagged a tolerability cost: tirzepatide showed about 32% higher discontinuation due to adverse events, driven by gastrointestinal effects ^[16]. Multiple pharmacovigilance analyses of the FDA Adverse Event Reporting System (FAERS) have characterised the real-world safety signal spectrum, with a 2025 FAERS disproportionality study finding that gastrointestinal events dominated the spontaneous-report database, with incorrect-dose-administration the single most-reported event type — underscoring the importance of correct titration ^[19]. Tirzepatide effects and tirzepatide references carry the full cited record.